CC
PHXM

Cannell & Co’s PHAXIAM Therapeutics S.A.. American Depositary Shares PHXM Stock Holding History

Cannell & Co’s Portfolio PHXM Stock Details PHXM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,600
Closed -$150K – 301
2021
Q3 		$150K Buy
+2,600
New +$146K ﹤0.01% 276

Other funds holding PHXM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cannell & Co's PHXM Position: Q4 2021 in Review

Cannell & Co sold out of PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) in Q4 2021, closing a stake of 2,600 shares — an estimated $150K sold.

Cannell & Co first reported a position in PHXM in Q3 2021 and held it in 1 quarter. The position peaked at $150K in Q3 2021. 9 funds tracked by Wall St. Rank hold PHXM as of Q4 2021.

  • Cannell & Co reported no remaining PHAXIAM Therapeutics S.A.. American Depositary Shares position as of Q4 2021 after selling out during the quarter.
  • Cannell & Co sold 2,600 PHAXIAM Therapeutics S.A.. American Depositary Shares shares in Q4 2021, an estimated $150K.
  • Cannell & Co first reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares in Q3 2021 and held it in 1 quarter.
  • Cannell & Co's PHAXIAM Therapeutics S.A.. American Depositary Shares position peaked at $150K in Q3 2021.
  • 9 funds tracked by Wall St. Rank held PHAXIAM Therapeutics S.A.. American Depositary Shares as of Q4 2021.

Based on Cannell & Co's 13F filing for Q4 2021, filed 9 Feb 2022.